EU approves Ruconest for HAE
This article was originally published in Scrip
Swedish Orphan Biovitrum is planning to launch Ruconest (conestat alfa) in Germany, the UK, Sweden, Finland and Denmark following today's news that the European Commission has approved the recombinant human C1 inhibitor to treat acute attacks of hereditary angioedema. Pharming, the Dutch biotech company that developed the drug, is now entitled to a €5 million milestone payment from its marketing and distribution partner
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.